ION337 not checked

Ionis Pharmaceuticals, Inc.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Dravet Syndrome
Main trialPhase 1/2
“The primary purpose of this study is to evaluate the safety and tolerability of ION337 in participants with Dravet syndrome (DS).”In the company’s words, NCT07531745 on ClinicalTrials.gov

Other drugs for Dravet Syndrome

All 7 drugs for Dravet Syndrome

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Recruiting Dec 2030 ASCEND: Safety and Tolerability of ION337 for the Treatment of Dravet Syndrome
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ION337

Following is part of Solo: you see every change to ION337 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in